Why Isotretinoin Is Not Recommended for Hidradenitis Suppurativa
Isotretinoin should not be used for hidradenitis suppurativa because it lacks efficacy in the majority of patients and may actually worsen the disease, particularly in those with the "conglobata phenotype."
Evidence Against Isotretinoin Use
The North American clinical management guidelines for HS 1 notably omit isotretinoin from all treatment recommendations across mild, moderate, and severe disease categories. This absence is deliberate and evidence-based.
Poor Efficacy Data
The largest patient-reported outcomes study demonstrates isotretinoin's failure in HS:
- 77% of patients reported no effect 2
- Only 16.1% reported improvement
- 6.9% experienced worsening of their HS 2
Long-term follow-up data confirms these disappointing results: only 16.2% of patients maintained improvement after treatment, with monotherapy having "limited therapeutic effect" 3. Even when some initial response occurs, it is typically not sustained.
Risk of Disease Exacerbation
Isotretinoin can paradoxically trigger or worsen HS, particularly in vulnerable populations 4. The mechanism is concerning: isotretinoin reduces sebaceous gland size and function, while HS lesions show reduced or absent sebaceous glands compared to normal skin 4. By further depleting sebaceous glands, isotretinoin may contribute to HS pathogenesis rather than treating it.
Recent data identifies specific high-risk patients 5:
- HS "conglobata phenotype" patients: 80% worsened on isotretinoin (p < 0.001)
- Male patients: 90% of those who worsened were men (p = 0.04)
- BMI >25 kg/m²: associated with worse outcomes
Guideline-Recommended Alternatives
Instead of isotretinoin, the North American guidelines 1 recommend:
For mild-to-moderate HS:
- Tetracyclines (12-week course or long-term maintenance)
- Clindamycin + rifampin combination (second-line)
- Hormonal agents in appropriate female patients
For moderate-to-severe HS:
- Adalimumab (FDA-approved, improves disease severity and quality of life)
- Infliximab
- Moxifloxacin + metronidazole + rifampin combination
Clinical Pitfalls to Avoid
Do not confuse acne conglobata with nodulocystic acne. While isotretinoin is highly effective for severe nodulocystic acne 6, it should be avoided in patients with both acne and HS who have the "conglobata phenotype" 5. These conditions resemble each other but respond differently to treatment.
Screen for HS before prescribing isotretinoin for acne. Question patients, particularly those with acne conglobata, about painful nodules in axillae, groin, or intertriginous areas before initiating isotretinoin 4.
When Isotretinoin Might Be Considered (Rare Exceptions)
Only 35.9% of HS patients showed any beneficial response to isotretinoin 7. The single predictor of potential response was history of pilonidal cyst (p = 0.024) 7. However, even in this subset, the response rate remains modest and does not justify routine use given the availability of superior alternatives.
Notably, having concomitant regular or cystic acne did not enhance HS treatment response to isotretinoin 7, further undermining its rationale in HS management.
Bottom Line
Isotretinoin is excluded from evidence-based HS treatment algorithms 1 because it fails to improve outcomes in most patients, carries risk of disease worsening (especially in conglobata phenotype), and we now have proven effective alternatives including adalimumab, combination antibiotics, and hormonal therapies that should be prioritized instead.